- Report
- May 2024
- 130 Pages
Global
From €5819EUR$6,499USD£5,065GBP
- Report
- May 2024
- 134 Pages
Global
From €5819EUR$6,499USD£5,065GBP
- Report
- January 2024
- 250 Pages
Global
From €7119EUR$7,950USD£6,196GBP
- Drug Pipelines
- December 2022
- 30 Pages
Global
From €2910EUR$3,250USD£2,533GBP
- Drug Pipelines
- December 2022
- 30 Pages
Global
From €2462EUR$2,750USD£2,143GBP
- Drug Pipelines
- December 2022
- 30 Pages
Global
From €2462EUR$2,750USD£2,143GBP
- Drug Pipelines
- December 2022
- 30 Pages
Global
From €2462EUR$2,750USD£2,143GBP
- Drug Pipelines
- December 2022
- 30 Pages
Global
From €2462EUR$2,750USD£2,143GBP
- Report
- November 2023
- 135 Pages
Global
From €3582EUR$4,000USD£3,117GBP
- Report
- January 2023
- 174 Pages
Global
From €3985EUR$4,450USD£3,468GBP
- Report
- February 2023
- 143 Pages
North America
From €3089EUR$3,450USD£2,689GBP
- Report
- August 2024
- 93 Pages
Global
From €3500EUR$4,187USD£3,153GBP

Treprostinil is a drug used to treat respiratory diseases such as pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). It is a prostacyclin analogue, meaning it works by mimicking the effects of prostacyclin, a naturally occurring hormone in the body that helps to regulate blood pressure in the lungs. Treprostinil is administered through a variety of methods, including oral tablets, subcutaneous injections, and inhalation. It is also available in a topical form for the treatment of Raynaud's phenomenon.
Treprostinil is a relatively new drug, having been approved by the FDA in 2002. It is used to treat a variety of respiratory diseases, including PAH, CTEPH, and Raynaud's phenomenon. It is also used to treat other conditions such as sickle cell anemia and cystic fibrosis.
The treprostinil market is a growing one, with many companies offering products and services related to the drug. Some of these companies include United Therapeutics, Actelion Pharmaceuticals, GlaxoSmithKline, and Pfizer. Show Less Read more